All sponsors

BeOne Medicines $ONC

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS29
PHASE 3 / 2-315
RECRUITING17
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO33%

Delay Index: of 21 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open BeOne Medicines on the live radar map → 📅 $ONC readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Sonrotoclax
NCT05471843
P1/2Active, not recruitingMantle Cell Lymphoma; Refractory Mantle Cell Lymphoma (MCL)1252025-07-18 (+17 mo)
MANGROVE
NCT04002297
P3Active, not recruitingMantle Cell Lymphoma; Non-Hodgkin Lymphoma5102026-04-27 (+58 mo)
Sonrotoclax
NCT05952037
P2Active, not recruitingWaldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinemia Recurrent1142026-09-22 (-13 mo)
Sonrotoclax
NCT04973605
P1/2RecruitingRelapsed/Refractory Multiple Myeloma2462026-11 (+38 mo)
Sonrotoclax
NCT06637501
P2Active, not recruitingChronic Lymphocytic Leukemia942026-11 (-11 mo)
Zanubrutinib
NCT04170283
P3Active, not recruitingB-cell Malignancies9552026-12-31 (+25 mo)
CaDAnCe-101
NCT05006716
P1/2RecruitingB-cell Malignancy; Marginal Zone Lymphoma6892027-03 (+38 mo)
BGB-B2033
NCT06427941
P1/2RecruitingMetastatic Hepatocellular Carcinoma; Local Advanced Hepatocellular Carcinoma6302027-03-31 (+5 mo)
Tacabrutideg
NCT05294731
P1/2RecruitingB-cell Malignancy; Non-Hodgkin Lymphoma1462027-06-30 (+4 mo)
ALMOND
NCT05707377
P2/3Active, not recruitingPrimary Membranous Nephropathy1782027-10 (-14 mo)
Subcutaneous Tislelizumab
NCT07043400
P3RecruitingMetastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma3512027-10-30
Tislelizumab
NCT07733180
P2RecruitingAdvanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma302028-02-28
BGB-B2033
NCT07911683
P2Not yet recruitingHepatocellular Cancer; Liver Cancer1002028-03-31
Tacabrutideg
NCT06973187
P3RecruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma5002028-04-17
CaDAnCe-302
NCT06846671
P3RecruitingCLL; Chronic Lymphocytic Leukemia2502028-05-15
MAHOGANY
NCT05100862
P3Active, not recruitingRelapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma7992028-07 (+2 mo)
Sonrotoclax
NCT06742996
P3RecruitingMantle Cell Lymphoma; B Cell Lymphoma3002028-08-31 (-7 mo)
BGB-11417
NCT04771130
P1/2RecruitingAcute Myeloid Leukemia; Myelodysplastic Syndromes2602028-08-31 (+79 mo)
Tacabrutideg
NCT06634589
P1/2RecruitingB-cell Malignancy; Relapsed Cancer802028-12-02
KANDELA-302
NCT07492641
P3RecruitingHR+/HER2- Breast Cancer10562029-04
BGB-B2033
NCT07836530
P3RecruitingHepatocellular Carcinoma; Liver Cancer4922029-09-21
Sonrotoclax
NCT06943872
P3RecruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma6302029-09-30
Sonrotoclax
NCT06697184
P1/2RecruitingChronic Lymphocytic Leukemia; CLL2582029-11-30 (+30 mo)
BG-C9074
NCT07811271
P3Not yet recruitingEpithelial Ovarian Cancer; Fallopian Tube Cancer6002029-11-30
CaDAnCe-303
NCT06970743
P3Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma1532029-11-30
sonrotoclax
NCT07770698
P1/2Not yet recruitingRelapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia302030-04-30
Sonrotoclax
NCT07277231
P3RecruitingChronic Lymphocytic Leukemia5002031-02
Tislelizumab
NCT07554521
P2RecruitingAdvanced Unresectable Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma302031-12-31
Sonrotoclax
NCT06073821
P3Active, not recruitingCLL6522032-02